Long-term follow-up of radiotherapy for prostate cancer

G. P. Swanson, M. W. Riggs, J. D. Earle

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Purpose To determine the long-term outcome of radiotherapy for prostate cancer. Methods and materials A total of 136 consecutive patients with prostate cancer underwent primary radiotherapy. All but 4 patients received 6000 cGy to the prostate. The minimal follow-up was 22.9 years. Results Of the 136 patients, 93 had Stage B (T2), 9 Stage A (T1), and 34 Stage C (T3). Sixty-nine percent of the patients developed recurrence, and 51% of all patients died of prostate cancer. The recurrences developed at a steady state throughout the length of follow-up. One half the recurrences occurred after 10 years, and recurrence was still observed >20 years after treatment. The survival rate at 5, 10, 15, 20, and 25 years was 81%, 59%, 37%, 16%, and 10%, respectively. The recurrence-free survival rate at 25 years was 17%. The median survival for Grade 3-4 patients was 6.3 years and for Grade 1-2 patients was 13.0 years. The median survival for those with T1 tumors was 12.9 years; T2 tumors, 12.4 years; and T3 tumors, 9.5 years. Conclusion Despite favorable early results, with long-term follow-up, patients continued to experience prostate cancer recurrence. Unless they died an intercurrent death, they were highly likely to develop recurrence and die of prostate cancer. The conclusions from treatment studies with <15 years of follow-up should be viewed as preliminary.

Original languageEnglish (US)
Pages (from-to)406-411
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume59
Issue number2
DOIs
StatePublished - Jun 1 2004
Externally publishedYes

Keywords

  • Long-term follow-up
  • Prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Fingerprint Dive into the research topics of 'Long-term follow-up of radiotherapy for prostate cancer'. Together they form a unique fingerprint.

Cite this